Does bronchoalveolar lavage lymphocytosis predict prognosis in fibrotic hypersensitivity pneumonitis, and is this relationship influenced by low-dose immunomodulatory therapy at the time of BAL? - Takeaways - MDSpire

Can Lymphocytosis Detected in Bronchoalveolar Lavage Serve as a Prognostic Indicator in Fibrotic Hypersensitivity Pneumonitis, and Does Low-Dose Immunomodulatory Therapy Affect This Correlation?

  • By

  • Punchalee Kaenmuang

  • Fiammetta Danzo

  • Simon Bax

  • Richard J. Hewitt

  • Maria Kokosi

  • Vasileios Kouranos

  • Felix Chua

  • Peter M. George

  • Gisli Jenkins

  • Athol U. Wells

  • Carmel J. W. Stock

  • Piersante Sestini

  • Elisabetta A. Renzoni

  • July 21, 2026

Share

  • 1

    Bronchoalveolar lavage (BAL) lymphocytosis is linked to improved prognosis in fibrotic hypersensitivity pneumonitis (fHP).

  • 2

    The study analyzed 247 fHP patients, with 162 untreated and 85 receiving immunomodulatory therapy during BAL.

  • 3

    Higher BAL lymphocyte percentages correlated with less severe disease and better one-year lung function changes in both treated and untreated patients.

  • 4

    BAL lymphocytosis independently predicted lower mortality in both untreated and treated fHP patients without treatment interaction effects.

  • 5

    The findings suggest that immunomodulatory therapy does not alter the prognostic value of BAL lymphocytosis in fHP.

Original Source(s)

Related Content